MESO earnings: next report 2026-09-04, real EPS beat/miss history, analyst consensus Buy, P/E -22.06. Updated 2026-07-23.
Mesoblast (MESO) Research Hub
Mesoblast (MESO) trades on NASDAQ, AU in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 15.48 USD (-4.09%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -22.06, market cap 2.12B. This hub links to the full technical, earnings and options research available for MESO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, AU |
| Last close | 15.48 USD (-4.09%) |
| 52-week range | 13.05 USD – 19.36 USD |
| Trend regime | Range |
| 14-day RSI | 46.7 (Neutral) |
| Trailing P/E | -22.06 |
| Market cap | 2.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-04 |
Available research for MESO
Covered Call on MESO: how it works, illustrative setup around the real 15.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MESO: how it works, illustrative setup around the real 15.48 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MESO: how it works, illustrative setup around the real 15.48 USD price, max profit/loss, breakeven and when to use it. Educational.
MESO technical analysis: range, last 15.48 USD, RSI 46.7, 52w range 13.05 USD–19.36 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MESO in?
Mesoblast (MESO) is classified under Healthcare (Biotechnology), listed on NASDAQ, AU.
Is MESO in an uptrend or downtrend?
As of 2026-09-11, MESO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MESO's trailing P/E ratio?
MESO's trailing P/E is -22.06, with a market cap of 2.12B. See the earnings research page for full valuation detail.
When does MESO next report earnings?
MESO is next scheduled to report earnings on 2026-09-04, with a consensus EPS estimate of -0.06733 USD.